Whitepapers / Playbooks

Summary

Global pharma and biotech companies are accelerating China+1 strategies to reduce over dependence on Chinese supply chains while preserving cost and capacity advantages. India has emerged as the leading "plus one" destination for small molecules and selected biologics, supported by the largest base of US FDA-compliant plants outside the US, a deep pool of CROs/CDMOs, and competitive labor costs.

This document proposes an end-to-end risk framework for designing and executing China+1 strategies in pharmaceuticals and biotechnology covering macro geostrategic risks, supply-chain and quality risks, regulatory and data-integrity risks, and partnership/ESG risks.